What question did this study set out to answer?

This review aims to evaluate antileukemic treatments for older adults with AML who cannot undergo standard therapy.

January 17, 2026Blood AdvancesOpen Access

Antileukemic therapies for older adults with AML ineligible for conventional therapy: systematic review & meta-analysis

View Full Paper

Ask AI

Bookmark

This review aims to evaluate antileukemic treatments for older adults with AML who cannot undergo standard therapy.
Conducted a systematic review of randomized controlled trials and non-randomized studies.
Included studies focused on adults aged 55 and older with newly diagnosed AML.
Compared efficacy and safety of therapies such as LDAC, AZA, DEC, and gemtuzumab ozogamicin.
AZA or LDAC combined with VEN probably reduces mortality and improves remission and quality of life.
AZA plus IDH1 inhibitors may reduce 1-year mortality and enhance remission and survival for IDH1-mutated AML.
Combination therapies generally showed inconsistent effects with low certainty of conclusions.

No takes yet. Share an insight, caveat, or question.

Systematic review finds new treatments can improve outcomes in older adults with acute myeloid leukemia, suggesting better care options.

Oliveros et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark